AU4787697A - Therapeutic gene - Google Patents

Therapeutic gene

Info

Publication number
AU4787697A
AU4787697A AU47876/97A AU4787697A AU4787697A AU 4787697 A AU4787697 A AU 4787697A AU 47876/97 A AU47876/97 A AU 47876/97A AU 4787697 A AU4787697 A AU 4787697A AU 4787697 A AU4787697 A AU 4787697A
Authority
AU
Australia
Prior art keywords
therapeutic gene
gene
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47876/97A
Other languages
English (en)
Inventor
Alan John Kingsman
Susan Mary Kingsman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of AU4787697A publication Critical patent/AU4787697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU47876/97A 1996-10-29 1997-10-28 Therapeutic gene Abandoned AU4787697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9622500 1996-10-29
GBGB9622500.8A GB9622500D0 (en) 1996-10-29 1996-10-29 Therapeutic gene
PCT/GB1997/002969 WO1998018934A1 (en) 1996-10-29 1997-10-28 Therapeutic gene

Publications (1)

Publication Number Publication Date
AU4787697A true AU4787697A (en) 1998-05-22

Family

ID=10802118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47876/97A Abandoned AU4787697A (en) 1996-10-29 1997-10-28 Therapeutic gene

Country Status (6)

Country Link
US (1) US6541219B1 (enExample)
EP (1) EP0941339A1 (enExample)
JP (1) JP2001503262A (enExample)
AU (1) AU4787697A (enExample)
GB (1) GB9622500D0 (enExample)
WO (1) WO1998018934A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924123B2 (en) * 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US6933377B2 (en) * 2002-07-29 2005-08-23 Qun Chen Compositions comprising multiple immunodeficiency virus subunits for inducing an immune response
JP5399612B2 (ja) * 2003-05-16 2014-01-29 アコーダ セラピューティクス、インク． Ｃｎｓを治療するための融合タンパク質
JP2012511033A (ja) * 2008-12-08 2012-05-17 テゴファーム コーポレーション 多価化合物の可逆阻害用マスキングリガンド
WO2012135389A2 (en) * 2011-03-28 2012-10-04 The Regents Of The University Of California Host cells and methods for oxidizing aromatic amino acids
US10400252B2 (en) * 2011-10-28 2019-09-03 Oxford Biomedica (Uk) Ltd. Catecholamine enzyme fusions
GB201118636D0 (en) * 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
JP6698114B2 (ja) * 2011-10-28 2020-05-27 オックスフォード バイオメディカ （ユーケー） リミテッド 構築物
HUE063051T2 (hu) 2013-02-15 2023-12-28 Bioverativ Therapeutics Inc Optimalizált VIII. faktor gén
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
ES2926585T3 (es) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Genes de Factor VIII optimizados
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
TWI773695B (zh) 2016-10-12 2022-08-11 美商生物維瑞提夫美國公司 抗Ｃ１ｓ抗體及其使用方法
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
JP7034499B2 (ja) 2017-06-27 2022-03-14 ニューラクル サイエンス カンパニー リミテッド 線維症の治療のための抗ｆａｍ１９ａ５抗体の用途
CN110972463B (zh) 2017-06-27 2024-05-28 纽洛可科学有限公司 抗序列相似家族19成员a5抗体在治疗青光眼中的用途
KR102574549B1 (ko) 2017-06-27 2023-09-07 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
CN111093700B (zh) 2017-06-27 2024-07-16 纽洛可科学有限公司 抗fam19a5抗体用于治疗癌症的用途
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
CA3090136A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
JP7171081B2 (ja) 2018-04-24 2022-11-15 ニューラクル サイエンス カンパニー リミテッド 神経病性疼痛の治療のための配列類似性１９、メンバーａ５抗体を有する抗ファミリーの用途
EP3790898A4 (en) 2018-05-10 2022-03-02 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
KR102648762B1 (ko) 2018-10-16 2024-03-19 주식회사 뉴라클사이언스 항-fam19a5 항체의 용도
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
TW202039855A (zh) 2018-12-06 2020-11-01 美商百歐維拉提夫治療公司 表現因子ｉｘ之慢病毒載體的用途
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
EP3902826A4 (en) 2018-12-27 2022-09-14 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT ATHEROSCLEROSIS
WO2020141452A1 (en) 2019-01-02 2020-07-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
EP4090430A1 (en) 2020-01-13 2022-11-23 Neoimmune Tech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
EP4093751A1 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
EP4093752A2 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
WO2021158783A1 (en) 2020-02-05 2021-08-12 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
BR112022026127A2 (pt) 2020-06-24 2023-01-17 Bioverativ Therapeutics Inc Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
US20230398216A1 (en) 2020-10-22 2023-12-14 Lyell Immunopharma, Inc. Chimeric activation receptors
KR20230098201A (ko) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 줄기 세포 동원의 유도 방법
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
CA3195594A1 (en) 2020-11-05 2022-05-12 Byung Ha Lee Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
JP2024520676A (ja) 2021-06-02 2024-05-24 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３欠損免疫細胞及びその使用
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
KR20240130705A (ko) 2021-12-30 2024-08-29 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
EP4615485A1 (en) 2022-11-07 2025-09-17 NeoImmuneTech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
CA1339654C (en) * 1988-06-03 1998-02-03 Ursula A. Germann Gene therapy using gene fusion for genetic or acquired disorders
WO1992007945A1 (en) * 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
US5344923A (en) 1992-09-29 1994-09-06 The Ohio State University Research Foundation Nucleotide sequence encoding for bifunctional enzyme for proline production
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6103226A (en) 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
AU1073797A (en) 1995-11-14 1997-06-05 Somatix Therapy Corporation Joint expression of gtp cyclohydrolase and tyrosine hydroxylase

Also Published As

Publication number Publication date
GB9622500D0 (en) 1997-01-08
WO1998018934A1 (en) 1998-05-07
EP0941339A1 (en) 1999-09-15
US6541219B1 (en) 2003-04-01
JP2001503262A (ja) 2001-03-13

Similar Documents

Publication Publication Date Title
AU4787697A (en) Therapeutic gene
AUPO203996A0 (en) Therapeutic uses
AU3737297A (en) Bacteriophage-mediated gene therapy
AU6418498A (en) Human genes
AU3882997A (en) Human telomerase gene
AU5198398A (en) Mutant human hedgehog gene
AU1184399A (en) Therapeutic molecules
AUPO434196A0 (en) An improved therapeutic
AU6254799A (en) Anti-ige gene therapy
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
AU5944898A (en) Catheter
AUPO060996A0 (en) Sexing gene
AU4582597A (en) Therapeutic proteins
AU5330198A (en) Therapeutic compounds
AUPP058797A0 (en) Novel gene
AU5524899A (en) Human deltex-like gene zdx
GB2333527B (en) Therapeutic gene
AUPO651397A0 (en) Therapeutic thermal-pack
AUPO537497A0 (en) Therapeutic molecules - II
AUPO112896A0 (en) Progestin-regulated gene
AUPO314896A0 (en) Therapeutic agent
AUPO937397A0 (en) Novel therapeutic molecules - II
AU3978697A (en) Plasmin-depletion therapy
AU2003200183A1 (en) Cholestrol-lowering Therapy
AUPO181796A0 (en) Therapeutic uses